PUBLISHER: Grand View Research | PRODUCT CODE: 1869877
PUBLISHER: Grand View Research | PRODUCT CODE: 1869877
The global coronary artery bypass graft market size was estimated at USD 19.24 billion in 2024 and is projected to reach USD 27.66 billion by 2033, growing at a CAGR of 3.86% from 2025 to 2033. Increasing the prevalence of cardiovascular disease is one of the key aspects driving market growth.
According to an Oxford Academic article published in January 2025, the global burden of cardiovascular disease remains substantial, with an age-standardized prevalence of approximately 7,179 cases per 100,000 individuals. This high prevalence underlines the growing need for effective treatment options, particularly for coronary artery disease, which is a leading contributor to cardiovascular-related morbidity and mortality.
The increasing incidence of CAD drives market growth. According to the CDC article published in October 2024, in the U.S., coronary artery disease (CAD) affects a significant portion of the population, with nearly 1 in 20 adults aged 20 years and older, approximately 5% living with the condition. This sizable patient pool highlights the ongoing clinical challenge posed by CAD, which remains a leading cause of heart-related morbidity and mortality. For many individuals, advanced cases of CAD require surgical intervention when less invasive treatments prove insufficient. As a result, coronary artery bypass grafting (CABG) continues to serve as a vital therapeutic approach, reinforcing its importance within the broader cardiovascular treatment landscape and underscoring its role as a key driver of market demand.
Advancements in graft technology are paving the way for more effective and durable solutions in CABG procedures. For instance, in July 2025, Xeltis, a transformative implant developer, introduced Xabg, a synthetic coronary artery bypass conduit (CABG). This innovative graft is designed to enable the natural creation of living and long-lasting vessels. Preliminary clinical data from an EU clinical trial have demonstrated positive safety and patency outcomes among patients with multi-vessel atherosclerotic coronary artery disease. Xabg represents a significant advancement in graft technology, aiming to address the limitations of traditional grafts by promoting endothelial cell growth and integration with the patient's vascular system.
Moreover, integrating robotics into CABG procedures transforms surgical approaches, offering enhanced precision and reduced invasiveness. According to OAE Publishing Inc., an article published in August 2025, Robotic-assisted CABG has emerged as a minimally invasive alternative to traditional open-heart surgery, offering reduced surgical trauma and faster recovery. Techniques include robotic-assisted minimally invasive direct coronary artery bypass (RA-MIDCAB), where the internal thoracic artery is harvested robotically and anastomosed via mini-thoracotomy, and totally endoscopic CABG (TECAB), which avoids thoracotomy altogether. These advancements reshape operative planning and execution, enhancing precision and reducing invasiveness in coronary revascularization procedures.
The landscape of CABG reimbursement in the U.S. is evolving rapidly, reflecting the healthcare industry's push toward value-based care. A significant trend is the introduction of bundled payment models that streamline reimbursement and incentivize quality. According to the American College of Cardiology Foundation in April 2024, the Centers for Medicare & Medicaid Services (CMS) proposed the Transforming Episode Accountability Model (TEAM), a mandatory hospital episode-based payment model set to start in January 2026. This model bundles payments for CABG surgeries and other high-cost procedures, ensuring more predictable reimbursement and encouraging hospitals to optimize care pathways for improved patient outcomes.
Parallel to bundled payments, physician fee schedule updates have shaped reimbursement trends. According to an Atricure article, effective January 1, 2025, the Medicare Physician Fee Schedule (PFS) revised reimbursement rates for CABG procedures, including the single arterial graft CABG (CPT code 33533) at approximately USD 1,789. These adjustments ensure payments align with current clinical practice and operational costs, reinforcing fair compensation for hospitals and surgeons performing complex cardiac procedures.
Moreover, expanding coverage for minimally invasive CABG techniques reflects increasing acceptance of advanced surgical approaches. As of January 2025, Blue Cross Blue Shield of Rhode Island updated its medical policy to cover Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery. The policy recognizes the benefits of less invasive procedures, such as reduced recovery times and enhanced patient outcomes. However, other minimally invasive approaches, such as Port Access CABG (PACAB) and Total Endoscopic CABG (TECAB), remain excluded due to limited evidence of improved outcomes.
Global Coronary Artery Bypass Graft Market Report Segmentation
This report forecasts revenue and volume growth at global, regional, and country levels and analyzes industry trends in each sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the global coronary artery bypass graft market report based on method, surgical procedure, end-use, and region: